Sun Pharma Q2 net falls 46.5% on Protonix provision

Sun Pharmaceutical Industries reported a 46.5 percent drop in quarterly net profit after it set aside Rs 5.84 billion towards a possible compensation in a patent dispute case related to drug Protonix.

The Mumbai-based drugmaker said consolidated net profit fell to Rs 3.2 billion during fiscal second quarter ended September from Rs 5.98 billion a year earlier. Net sales rose 40.2 percent to Rs 26.57 billion.

Analysts had estimated the net profit at Rs 7.68 billion, according to Thomson Reuters I/B/E/S.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Lower listings rate is proof that the Indian market is maturing

    The bullishness on Dalal Street notwithstanding, the pace at which new companies are being listed on Indian stock exchanges is declining.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Kumar Jain

Building great cities (and nations)

Fifteen to twenty years’ span is the time when humans ...

Rajgopal Nidamboor

The essence of amplified action

It is something that ‘separates’ us from other living creatures. ...

Shona Adhikari

All roads lead to Delhi, as it gears up for art fair

With the seventh edition of India Art Fair (IAF) coming ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture